This article was originally published on PharmaTimes http://www.pharmatimes.com/news/fda_set_to_review_sanofis_isatuximab_for_multiple_myeloma_1294351

Multiple myeloma is the second most common hematologic malignancy, affecting more than 138,0002 people worldwide.

Related Posts